Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Bloomage BioTechnology Corporation Limited

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 00963) COMPLETION OF SUBSCRIPTION OF UNLISTED WARRANTS UNDER SPECIFIC MANDATE

The Board is pleased to announce that the Warrant Subscription was completed on
27 December 2013, and 16,600,000 Warrants were issued to the Subscriber pursuant to the terms of the Warrant Subscription Agreement.

Reference is made to the announcement of Bloomage BioTechnology Corporation Limited (the "Company") dated 29 October 2013 in relation to the proposed subscription of unlisted warrants under specific mandate (the "Announcement"). Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as those defined in the Announcement.
The Board is pleased to announce that the Warrant Subscription was completed on 27
December 2013, and 16,600,000 Warrants were issued to the Subscriber pursuant to the terms of the Warrant Subscription Agreement.
Upon exercise in full of the subscription rights attaching to the Warrants at the initial Exercise Price of HK$16.652, a maximum of 16,600,000 Warrant Shares will be issued and allotted, representing approximately 5% of the existing issued share capital of the Company as at the date of this announcement and approximately 4.76% of the issued share capital of the Company as enlarged by the issue and allotment of the Warrant Shares.
Set out below are the shareholding structure of the Company as at the date of this announcement and immediately after the full exercise of the subscription rights attaching to the Warrants (assuming there are no other changes in the issued share capital of the Company): -
- 1 -

As at the date of this announcement Approximate Immediately after the full exercise of the subscription rights attaching to the Warrants (assuming there are no other changes in the issued share capital of the Company): Approximate No. of Shares % No. of Shares %

AIM First Investments

Limited ("AFI") (Note 1)

182,520,000

54.98

182,520,000

52.36

The Subscriber (Note 2)

--

--

16,600,000

4.76

Forever Shining Holdings

Limited ("Forever

Shining") (Note 3)

4,544,000

1.37

4,544,000

1.30

Public Shareholders

144,936,000

43.65

144,936,000

41.58

Total 332,000,000 100 348,600,000 100

Notes:

(1) The 182,520,000 existing Shares are held by AFI. AFI is wholly-owned by Ms. Zhao Yan, the chairman of the Company and an executive Director. By virtue of her interest in AFI, Ms. Zhao Yan is deemed to be interested in such 182,520,000 Shares held by AFI for the purpose of the SFO.

(2) As at the date of this announcement, the entire issued share capital of the Subscriber is owned by Mr. Jin, an executive Director of the Company.

(3) The 4,544,000 existing Shares are held by Forever Shining, which is owned as to 42.86% by Ms.

Liu Aihua, an executive Director. By virtue of her interest in Forever Shining, Ms. Liu Aihua is deemed to be interested in such 4,544,000 Shares held by Forever Shining for the purpose of SFO.

(4) As at the date of this announcement, 2,190,000, 700,000, 680,000 and 6,950,000 Share Options were granted to Ms. Liu Aihua, Mr. Guo Jiajun, Ms. Wang Aihua and Mr. Jin, respectively, all being Directors, pursuant to the Share Option Scheme.

Hong Kong, 27 December 2013
By order of the Board

Bloomage BioTechnology Corporation Limited ZHAO YAN

Chairman

As at the date of this announcement, the executive Directors are Ms. Zhao Yan, Mr. Jin Xuekun, Ms. Liu Aihua and Ms. Wang Aihua; the non-executive Director is Mr. Guo Jiajun; the independent non-executive Directors are Ms. Zhan Lili, Mr. Zhang Fuping and Mr. Qin Bin.

- 2 -

distributed by